Back to top
more

DIADEXUS INC (DDXS)

(Delayed Data from OTC)

$0.01 USD

0.01
67,488

-0.01 (-35.00%)

Updated Jun 21, 2016 02:15 PM ET

Add to portfolio

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1
2
3
4
5
S&P
Strong Buy
Buy
Hold
Sell
Strong Sell
500
24.62%
17.69%
9.40%
5.11%
2.01%
10.65%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

NA Value | NA Growth | NA Momentum | NA VGM

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

View All Zacks #1 Ranked Stocks

Trades from $1

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Brokerage Reports

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

0 items in cart

diaDexus Inc. [DDXS]

Reports for Purchase

Showing records 1 - 20 ( 27 total )

Company: diaDexus Inc.

Industry: Medical - Products

Record: 1

09/03/2014

Company Report

Pages: 7

SOLID-TIMI results presented at ESC, reiterate STRONG BUY

Provider: FELTL & COMPANY

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: diaDexus Inc.

Industry: Medical - Products

Record: 2

08/25/2014

Company Report

Pages: 4

We are suspending coverage in order to focus on other areas of interest to our institutional clients

Provider: Stonegate Securities

Analyst: TRANG D

Price: 10.00

Research Provided by a Third Party

Company: diaDexus Inc.

Industry: Medical - Products

Record: 3

07/29/2014

Company Report

Pages: 8

Q2 results beat, GSK agreement enters second phase, reiterate STRONG BUY

Provider: FELTL & COMPANY

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: diaDexus Inc.

Industry: Medical - Products

Record: 4

05/14/2014

Company Report

Pages: 7

Darapladib trial disappoints, thesis intact, reiterate STRONG BUY

Provider: FELTL & COMPANY

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: diaDexus Inc.

Industry: Medical - Products

Record: 5

05/12/2014

Company Report

Pages: 12

Research Update: Results a little under the weather but progressing in its product pipeline

Provider: Stonegate Securities

Analyst: TRANG D

Price: 25.00

Research Provided by a Third Party

Company: diaDexus Inc.

Industry: Medical - Products

Record: 6

05/08/2014

Company Report

Pages: 8

Q1 misses, guidance raised, reiterate STRONG BUY, price target to $2.40

Provider: FELTL & COMPANY

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: diaDexus Inc.

Industry: Medical - Products

Record: 7

05/02/2014

Company Report

Pages: 7

Trifecta of positive developments this week, reiterate STRONG BUY, $2.90PT

Provider: FELTL & COMPANY

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: diaDexus Inc.

Industry: Medical - Products

Record: 8

03/31/2014

Company Report

Pages: 7

STABILITY data appears to back Lp-PLA2 as marker, reiterate STRONG BUY, $2.90PT

Provider: FELTL & COMPANY

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: diaDexus Inc.

Industry: Medical - Products

Record: 9

03/13/2014

Company Report

Pages: 12

Signs agreement with Thermo to develop diagnostic test

Provider: Stonegate Securities

Analyst: TRANG D

Price: 25.00

Research Provided by a Third Party

Company: diaDexus Inc.

Industry: Medical - Products

Record: 10

03/13/2014

Company Report

Pages: 12

Research Update: Signs agreement with Thermo to develop diagnostic test

Provider: Stonegate Securities

Analyst: TRANG D

Price: 25.00

Research Provided by a Third Party

Company: diaDexus Inc.

Industry: Medical - Products

Record: 11

03/06/2014

Company Report

Pages: 11

Q4 slightly ahead, 3 new tests licensed from TMO, reiterate STRONG BUY

Provider: FELTL & COMPANY

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: diaDexus Inc.

Industry: Medical - Products

Record: 12

11/12/2013

Company Report

Pages: 8

Darapladib study fails to meet primary endpoint, DDXS selloff overdone, reiterate SB

Provider: FELTL & COMPANY

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: diaDexus Inc.

Industry: Medical - Products

Record: 13

11/12/2013

Company Report

Pages: 12

Results from GSK trial disappoint but outlook for business remains unchanged.

Provider: Stonegate Securities

Analyst: TRANG D

Price: 25.00

Research Provided by a Third Party

Company: diaDexus Inc.

Industry: Medical - Products

Record: 14

11/06/2013

Company Report

Pages: 12

Research Update: DDXS: And the revenues growth keeps going and going

Provider: Stonegate Securities

Analyst: TRANG D

Price: 25.00

Research Provided by a Third Party

Company: diaDexus Inc.

Industry: Medical - Products

Record: 15

10/30/2013

Company Report

Pages: 8

Q3 2013 results beat, reiterating STRONG BUY, raising PT to $2.90

Provider: FELTL & COMPANY

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: diaDexus Inc.

Industry: Medical - Products

Record: 16

10/16/2013

Company Report

Pages: 7

PLAC Activity test clinical program advances after FDA meeting

Provider: FELTL & COMPANY

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: diaDexus Inc.

Industry: Medical - Products

Record: 17

09/13/2013

Company Report

Pages: 10

Notes from the road - company HQ visit and non-deal road show - raise PT to $2.15

Provider: FELTL & COMPANY

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: diaDexus Inc.

Industry: Medical - Products

Record: 18

08/19/2013

Company Report

Pages: 12

Q2FY13 results above expectations as physicians become aware of PLAC test benefits

Provider: Stonegate Securities

Analyst: TRANG D

Price: 25.00

Research Provided by a Third Party

Company: diaDexus Inc.

Industry: Medical - Products

Record: 19

08/19/2013

Company Report

Pages: 12

Q2FY13 results above expectations

Provider: Stonegate Securities

Analyst: TRANG D

Price: 25.00

Research Provided by a Third Party

Company: diaDexus Inc.

Industry: Medical - Products

Record: 20

08/09/2013

Company Report

Pages: 7

Q2 2013 results heartening, reiterating STRONG BUY, raising PT to $1.80

Provider: FELTL & COMPANY

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party